Pharsight

Drugs that contain Elagolix Sodium

1. Orilissa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(6 months from now)

US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jul, 2024

(4 months from now)

US11344551 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(10 years from now)

US10537572 ABBVIE INC Methods of administering elagolix
Sep, 2036

(12 years from now)

US10682351 ABBVIE INC Methods of administering elagolix
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

NCE-1 date: 2022-07-23

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to r...

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents

2. Orilissa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11542239 ABBVIE Elagolix sodium compositions and processes
Jul, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11707464 ABBVIE Methods of treating heavy menstrual bleeding
Mar, 2034

(10 years from now)

US11690854 ABBVIE Methods of treating heavy menstrual bleeding
Apr, 2038

(14 years from now)

US11690845 ABBVIE Methods of administering elagolix
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

NCE-1 date: 2022-07-23

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg elagolix for up to 24 months; Management of moderate to severe pain associated with endometriosis in a patient with mod...

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents